Power Law company profile

Anbio Biotechnology

Biotech & Life Sciences · Frankfurt, Germany · Founded 2021 · IPO 2025 Unicorn

Supplier of laboratory and POCT diagnostic instruments for biomarker detection across diverse diseases

Valuation

$1.22B

Market cap · May/2026

Revenue

$8.6M

Latest reported FY

EBITDA

$5.3M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Global footprint

Where Anbio Biotechnology has talent and traffic

Workforce by country

5 countries with
team presence

🇨🇳 China38.9%

🇨🇱 Chile19.4%

🇯🇵 Japan19.4%

🇬🇧 United Kingdom19.4%

🇦🇺 Australia16.7%

5 countries shown

Patent intelligence

$1M patent portfolio · 55 active families

Estimated portfolio value

$1M

0.11% of market cap · 188.7× smaller than top peer HeartFlow ($247M)

55 active patent families

Where Anbio Biotechnology innovates PhysicsMechanical engineeringAssembly lineAnalytical chemistryIndustrial engineering

Where Anbio Biotechnology concentrates vs peers

Each axis is a top-10 topic across Anbio Biotechnology and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Anbio Biotechnology

An AI-synthesized read of the highest-engagement posts about Anbio Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Anbio Biotechnology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles